Thyroid Transcription Factor 1 Immunohistochemistry as an Intraoperative Diagnostic Tool at Frozen Section for Distinction Between Primary and Secondary Lung Tumors

2007 ◽  
Vol 131 (4) ◽  
pp. 582-587
Author(s):  
David N. Butcher ◽  
Peter Goldstraw ◽  
George Ladas ◽  
Michael E. Dusmet ◽  
Mary N. Sheppard ◽  
...  

Abstract Context.—Intraoperative distinction between primary and metastatic carcinomas in the lung at frozen section remains problematic. Objective.—To assess the value and practicality of immunohistochemistry for thyroid transcription factor 1 at the time of intraoperative frozen section. Design.—Thirty-three patients presented with either a solitary pulmonary mass or 2 pulmonary masses and a history of carcinoma in a different organ. In addition to routine frozen section for assessment of tumor type, we looked for expression of thyroid transcription factor 1, using the EnVision system with abridged methodology. Results.—Ten cases were positive for thyroid transcription factor 1, which was confirmed on subsequent paraffin sections. Nine of these were confirmed as primary pulmonary adenocarcinomas, but 1 case proved to be a rare false-positive metastatic colonic carcinoma. Twenty-three cases were negative on frozen section and reported as favoring metastatic disease. In all cases, additional immunohistochemical data increased diagnostic confidence, but particularly in cases of positive primary pulmonary tumors and in cases with disease metastatic from sites other than the large bowel. The average time in addition to that of the basic frozen section was 24 minutes per test with a cost of £32 (US$57). Conclusions.—Frozen section immunohistochemistry for thyroid transcription factor 1 shows specificity and sensitivity similar to those seen for formalin-fixed tissues and is feasible within the time frame of a thoracotomy. Diagnostic confidence is increased, especially with positive primary pulmonary tumors. However, its practice should be properly planned within an operative procedure as liberal usage will likely have significant staff and cost implications.

2005 ◽  
Vol 42 (3) ◽  
pp. 315-320 ◽  
Author(s):  
J. A. Ramos-Vara ◽  
M. A. Miller ◽  
G. C. Johnson

In a previous study, we characterized the reactivity of monoclonal antibody (MoAb) 8G7G3/1 to thyroid transcription factor-1 (TTF-1) in canine thyroid tumors. In this study, we have examined the reactivity of this antibody in 120 canine pulmonary tumors, including 78 primary epithelial tumors. Tissues had been fixed in formalin and routinely processed for histopathology. Nuclear staining for TTF-1 was detected in 64.2% of primary pulmonary epithelial tumors. The most common TTF-1-reactive tumor types were bronchioloalveolar carcinomas and bronchogenic carcinomas. Staining was diffuse, heterogeneous, or patchy. Nonpulmonary, metastatic epithelial tumors, except two of two thyroid carcinomas, did not react with antibody 8G7G3/1. Mesotheliomas and other mesenchymal tumors were also negative for this marker. A reduction or loss of reactivity was apparent in pulmonary epithelial tumors archived in paraffin blocks for 7-8 years. There was slight reduction in the number of positive cells or the intensity of the reaction in control tissues fixed longer than 1 week. On the basis of our limited studies and the human literature, it appears that MoAb 8G7G3/1 to TTF-1 is a highly specific (with the exception of thyroid tumors) and moderately sensitive marker for canine pulmonary epithelial tumors.


Endocrinology ◽  
1998 ◽  
Vol 139 (6) ◽  
pp. 3014-3017 ◽  
Author(s):  
Koichi Suzuki ◽  
Yoshihiko Kobayashi ◽  
Ryohei Katoh ◽  
Leonard D. Kohn ◽  
Akira Kawaoi

2011 ◽  
Vol 207 (11) ◽  
pp. 686-690 ◽  
Author(s):  
Matthias Dettmer ◽  
Tae Eun Kim ◽  
Chan Kwon Jung ◽  
Eun Sun Jung ◽  
Kyo Young Lee ◽  
...  

In Vivo ◽  
2018 ◽  
Vol 32 (6) ◽  
pp. 1571-1579 ◽  
Author(s):  
ROLANDAS ZABLOCKIS ◽  
EDVARDAS ŽURAUSKAS ◽  
EDVARDAS DANILA ◽  
VYGANTAS GRUSLYS

Sign in / Sign up

Export Citation Format

Share Document